IAPP and type 2 diabetes mellitus: There is currently no information on the impact of pramlintide use on CD induced by type 2 diabetes mellitus (T2DM), even though it is a nontoxic version of amylin that stimulates many metabolic pathways and does not aggregate as amylin also [45].